Month: April 2020

UPM-Kymmene Corporation    Stock Exchange Release (Interim Report)              23 April 2020 at 09:45 EETUPM Interim Report Q1 2020:Solid Q1 results, UPM well prepared for the current uncertainty and future recoveryQ1 2020 highlightsSales decreased by 15% to EUR 2,287 million (2,693 million in Q1 2019) due to lower pulp and paper prices and lower deliveries of graphic papersComparable EBIT decreased by 26% to EUR 279 million (374 million)UPM Raflatac and UPM Specialty Papers achieved record comparable EBITThe industry-wide strike in Finland affected UPM’s pulp and paper businesses for two weeks and timber and plywood businesses for four weeksThe COVID-19 pandemic did not materially impact UPM’s operations in Q1 2020UPM implemented extensive precautions to protect the health and safety of its employees and to ensure business...

UPM-Kymmene Oyj                   Pörssitiedote (Osavuosikatsaus)                        23.4.2020 klo 09.45 EETUPM osavuosikatsaus Q1 2020:Vahva Q1 tulos, UPM varautunut tämän hetken epävarmuuteen ja valmis tulevaan elpymiseenQ1 2020 lyhyestiLiikevaihto laski 15 % ja oli 2 287 (Q1 2019: 2 693) miljoonaa euroa, lasku johtui alemmista sellun ja paperin hinnoista sekä graafisten paperien toimitusten vähenemisestäVertailukelpoinen liikevoitto laski 26 % ja oli 279 (374) miljoonaa euroaUPM Raflatacin ja UPM Specialty Papersin vertailukelpoinen liikevoitto oli ennätyksellinenTeollisuudenalan lakko Suomessa vaikutti UPM:n sellu- ja paperiliiketoimintoihin kahden viikon ajan ja saha- ja vaneriliiketoimintoihin neljän viikon ajanCOVID-19 -pandemia ei vaikuttanut merkittävästi UPM:n toimintaan ensimmäisellä vuosineljännekselläUPM toteutti mittavia...

Signature of an exclusive agreement with the Japanese distributor MURANAKA Medical InstrumentsSpineway, specialist in designing innovative surgical implants and instruments for treating severe disorders of the spinal column, announces the signature of an exclusive agreement for the distribution of its products in Japan with MURANAKA Medical Instruments.This agreement follows on the heels of the approval last October by the Japanese health authorities of Spineway’s Mont-Blanc MIS minimally invasive surgical line. Thanks to established know-how on the Asian continent, Spineway will be able to rely on the sales network and expertise of one of the biggest importers/distributers of medical equipment in Japan to distribute its products on this territory.Based in Osaka, MURANAKA boasts annual revenue of over 300 million euros and is established...

2020 Annual General Meeting – NoticeNotice is hereby given that the 2020 Annual General Meeting of BW Energy Limited will be held at Washington Mall Phase 2, 4th Floor, Suite 400, 22 Church Street, HM 1189, Hamilton HM EX, Bermuda, on 19 May 2020 at 13:00 (Bermuda time).Please see the attached documents in relation to the Annual General Meeting:Chairman’s LetterNotice of the 2020 AGM Form of ProxyAppendix I of the Notice – Guidelines for the Nomination CommitteeAppendix II of the Notice – Amended Bye-lawsFor further information, please contact:Knut R. Sæthre, CFO BW Energy, +47 91 11 78 76ir@bwenergy.noAbout BW Energy:BW Energy is a growth E&P company with a differentiated strategy targeting proven offshore oil and gas reservoirs through low risk phased developments. The Company has access to existing FPSOs to reduce time to first...

First quarter in briefActive Biotech announces new directionPatent regarding use of tasquinimod in the treatment of multiple myeloma granted in JapanEvents after the end of the periodDue to the current situation with the COVID-19 pandemic the Investment day planned to be held in connection with the Annual general meeting will be postponed to a later timepointFinancial summaryFor further information, please contact:The report is also available at www.activebiotech.com.Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact person set out above, for publication on April 23, 2020, at 08.30 a.m. CET. AttachmentActive Biotech Interim Report January – March 2020

Kvartal 1 i korthetActive Biotech offentliggör ny inriktningPatent beviljat i Japan för användning av tasquinimod i multipelt myelomHändelser efter periodens utgångMed anledning av COVID-19-pandemin kommer det i samband med Årsstämman planerade investerarmötet att skjutas upp till en senare tidpunktEkonomisk översiktFör ytterligare information, vänligen kontakta:Rapporten finns även tillgänglig på www.activebiotech.com.Active Biotech är skyldigt att offentliggöra informationen i denna delårsrapport enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, den 23 april, 2020, kl. 08.30 CET. BilagaActive Biotech Delårsrapport januari – mars 2020

Suominen Corporation’s Interim Report on April 23, 2020 at 9:30 a.m. (EEST)In this financial report, figures shown in brackets refer to the comparison period last year if not otherwise stated.Outlook for 2020 updatedPrevious outlook for 2020 on January 29, 2020:Suominen expects that in 2020 its comparable operating profit will improve from 2019. In 2019, Suominen’s operating profit amounted to EUR 8.1 million.Petri Helsky, President & CEO:Our net sales remained at the same level as in the comparison period and amounted to EUR 110.2 million (109.8). Sales volumes increased but sales prices decreased following the lower raw material prices. The positive impact from currencies on net sales was EUR 1.4 million.The COVID-19 pandemic increased sales volumes in all our markets towards the end of the quarter and in the short term the higher...

Suominen Oyj:n Osavuosikatsaus 23.4.2020 klo 9.30Tässä osavuosikatsauksessa sulkeissa esitetyt luvut viittaavat viime vuoden vastaavaan ajankohtaan, ellei muuta ole mainittu.Tammi-maaliskuu 2020 lyhyesti:Näkymät vuodelle 2020 päivitettySuominen arvioi vertailukelpoisen liikevoiton paranevan selvästi vuodesta 2019. On kuitenkin huomioitava, että tulosennuste vuoden jälkipuoliskolle on epävarma johtuen COVID-19 pandemiasta. Vuonna 2019 Suomisen liikevoitto oli 8,1 milj. euroa. Tilikausilla 2020 ja 2019 Suomisella ei ollut liikevoiton vertailukelpoisuuteen vaikuttavia eriä.Aikaisemmat näkymät vuodelle 2020, julkaistu 29.1.2020:Suominen arvio vertailukelpoisen liikevoiton paranevan vuodesta 2019. Vuonna 2019 Suomisen liikevoitto oli 8,1 milj. euroa.Petri Helsky toimitusjohtaja:Liikevaihtomme pysyi vertailukauden tasolla ja oli 110,2 milj....

Hässleholm, Sweden, April 23, 20203 Months December 2019 – February 2020Net sales 259.4 (370.2) MSEK.EBIT 53.0 (25.9) MSEK. Profit before tax 57.7(31.2) MSEK. Net profit 75.7 (38.7) MSEK.Earnings per share, before and after dilution equals 3.04 (1.55) SEK.During the three month period 0 (3) wind turbines were taken into operations with a total installed capacity of 0 (10.8) MW.During the three month period the equivalent of 1 (3) wind turbines with an installed capacity of 0.8 (10.8) MW was handed over to customers.At the end of the period Eolus had 687 (421) MW under asset management.In December 2019, Aquila Capital acquired all shares in Øyfjellet Wind AS, that holds the rights to establish wind farm Øyfjellet with a capacity of 400 MW. Eolus will handle the construction management of the wind farm on behalf of the customer.Significant...

Hässleholm den 23 april 2020Verksamhetsårets andra period 1 december 2019 – 29 februari 2020Nettoomsättningen uppgick till 259,4 (370,2) MSEK.Rörelseresultatet uppgick till 53,0 (25,9) MSEK. Resultat före skatt uppgick till 57,7 (31,2) MSEK. Periodens resultat efter skatt uppgick till 75,7 (38,7) MSEK.Resultat per aktie före och efter utspädning uppgick till 3,04 (1,55) SEK.Under perioden togs 0 (3) nya vindkraftverk med en total effekt om 0 (10,8) MW i drift.Under perioden överlämnades motsvarande 1,0 (3,0) vindkraftverk med en total effekt om 0,8 (10,8) MW till kund.Vid periodens utgång omfattade koncernens förvaltningsverksamhet 687 (421) MW.I december 2019 tillträdde Aquila Capital samtliga aktier i Øyfjellet Wind AS, som äger rättigheterna att etablera vindpark Øyfjellet med en effekt om 400 MW. Eolus hanterar byggnationen av vindparken...